Structure Therapeutics (GPCR) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Taysha Gene Therapies (TSHA) over the past year, losing 9.8% versus a loss of 12.5%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.44 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | TSHA |
|---|---|---|
| Share price | $25.67 | $4.43 |
| Market cap | $1.83B | $1.44B |
| 1-day change | -3.79% | 0.00% |
| YTD return | -63.09% | -19.45% |
| 1-year return | -9.77% | -12.45% |
| 5-year return | — | -75.22% |
| EPS (TTM) | $-3.03 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.77M |
| Revenue growth (YoY) | — | +17.28% |
| Net income (latest FY) | $-141.20M | $-109.00M |
| Operating margin | — | -1130.65% |
| Net margin | — | -1115.27% |
| 52-week high | $94.90 | $7.30 |
| 52-week low | $25.09 | $3.69 |
| Distance from 52-week high | -72.95% | -39.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +312.08% | +193.45% |
| Average volume | 965.00K | 3.28M |
| Shares outstanding | 71.31M | 325.83M |
| Employees | 281 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
GPCR vs TSHA FAQ
Which is bigger, Structure Therapeutics or Taysha Gene Therapies?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.44B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, GPCR or TSHA?
GPCR returned -9.77% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Taysha Gene Therapies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Structure Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Taysha Gene Therapies.